COR Medical Ventures is a San Diego-area medical device development company that acts as the center of rotation for medtech innovation. Through three branches - consulting services, a venture studio, and distribution services - it partners with surgeon-inventors and corporations to take orthopedic, spine, and other devices from clinical idea to FDA clearance and market launch. Founded by engineer Ben Arnold, the firm has stood up a portfolio of more than a dozen independent companies spanning robotics, wearables, spinal fusion, and soft-tissue fixation.
Tenon Medical is a Los Gatos, California medical device company that built the Catamaran SI Joint Fusion System, a patented, less-invasive way to fuse the sacroiliac joint with a single titanium implant placed along an inferior-posterior trajectory. Founded in 2012 and public on the Nasdaq since 2022 (TNON), Tenon targets the often-overlooked SI joint, a frequent and hard-to-diagnose source of chronic lower-back pain. In 2025 it expanded into a multi-product sacro-pelvic platform by acquiring the SiVantage SImmetry technology portfolio.
Cerapedics is a commercial-stage ortho-biologics company that engineered a synthetic 15-amino-acid peptide, P-15, to coax the body into building bone faster. Its FDA-approved i-FACTOR is used in cervical spine fusions, and its 2025 PearlMatrix approval made it the first and only proven bone growth accelerator cleared for lumbar fusion.
Valeska Schroeder, Ph.D., is CEO and Chairman of the Board at Cerapedics Inc., the Colorado-based orthobiologics company behind i-FACTOR and PearlMatrix - two of only three FDA PMA-approved bone grafts on the U.S. spine market. A materials scientist by training (BS, MS, PhD from UC Berkeley), she spent the first part of her career in medtech product development before transitioning to venture investing at KCK MedTech, where she led deals and sat on boards of companies including Sight Sciences, Aerin Medical, Intuity Medical, and Lungpacer. She joined Cerapedics' board in 2018, deepened her involvement in 2021, and took the helm as CEO in November 2022, steering the company through PearlMatrix's landmark FDA approval in June 2025 - making Cerapedics the only company with two PMA-approved spinal biologics.